/ /

  • linkedin
  • Increase Font
  • Sharebar

    Innovation in glaucoma thriving

    advances in pharmaceuticals, devices, and diagnostics fueling growth for sector

    Big Pharma is on the hunt for new glaucoma drugs. Evidence to date says they are closing on new approvals.

    “The pace of therapeutic development is picking up in a big way,” said Stuart Abelson, MBA, president and CEO of Ora, an ophthalmic contract research organization. “Capital is flowing and programs are moving forward in all phases. Ora’s business is growing for a second year in a row at over 100%, adding resources and helping companies move their programs along.”

    Abelson co-moderated an overview of “New Horizons in Glaucoma Pharmaceuticals” session with Joel Schuman, MD, FACS, chairman of the Ophthalmology Department, University of Pittsburgh. The session highlighted four companies with strong new drug candidates.

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results